Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study

BACKGROUND: Extended dosing of the erythropoiesis-stimulating agent (ESA) darbepoetin alfa (DA) once biweekly or monthly reduces anaemia treatment burden. This observational study assessed outcomes and dosing patterns in patients with chronic kidney disease not on dialysis (CKD-NoD) commencing exten...

Descripción completa

Detalles Bibliográficos
Autores principales: Galle, Jan-Christoph, Addison, Janet, Suranyi, Michael G., Claes, Kathleen, Di Giulio, Salvatore, Guerin, Alain, Herlitz, Hans, Kiss, István, Farouk, Mourad, Manamley, Nick, Wirnsberger, Gerhard, Winearls, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
CLINICAL SCIENCE
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5146706/
https://www.ncbi.nlm.nih.gov/pubmed/27190334
http://dx.doi.org/10.1093/ndt/gfw047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5146706/
https://www.ncbi.nlm.nih.gov/pubmed/27190334
http://dx.doi.org/10.1093/ndt/gfw047

Ejemplares similares